Sarepta Therapeutics saw its stock skid 11% after the company announced preliminary unaudited 2025 sales results that missed analyst forecasts for its marketed Elevidys® (delandistrogene ...
Stopping cancer cells from entering a soft biomechanical state could help the immune system clear dormant cancer metastasis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback